Comment from Jitendra Pund

Dear Sir/Madam, Please find here with my comments on the line number from 287 to 303 Investigation Plan and Conducting Investigations 1. Purpose and Scope FDA recommends that establishments prepare a formal investigation plan with a detailed protocol and methodology. A comprehensive plan demonstrates that the establishment is addressing both the specific FDA 483 observations and the underlying systemic issues. The scope should be: i) Scientifically justified and risk based. ii) Inclusive of all relevant operations. iii) Supported by clear justification for any exclusions. 2. Regulatory Basis For finished drug products, 21 CFR 211.192 requires: i) Thorough investigation of unexplained discrepancies or batch/component failures to meet specifications. ii) Review of other batches of the same drug product and potentially other associated drug products. iii) A written record of the investigation, including conclusions and follow-up actions. 3. Key Components of the Investigation Plan A robust plan should include: i) Detailed protocol and methodology for conducting the investigation. ii) Trend analysis to identify recurring or related issues. iii) Linkage of connected FDA 483 observations to ensure systemic evaluation. iv) Risk assessment to evaluate impact on product quality and patient safety. v) Root cause analysis to identify and eliminate underlying problems. vi) Corrective and preventive actions (CAPA) to prevent recurrence. 4. Documentation and Follow-Up i) Maintain a written record of all investigations. ii) Include conclusions, supporting data, and follow-up actions. iii) Ensure documentation is clear, complete, and contemporaneous. 5. Applicability Across Products FDA recommends applying the same comprehensive approach to all drug products, not only those directly associated with the FDA 483 observations. This ensures consistency, compliance, and protection of patient safety. Regards Jitendra Pund